Stocks Health care RXST
NASDAQ · Health careRxSight, Inc. (RXST)
RxSight, Inc. brought in $121.8M of revenue over the twelve months to September 30, 2026, down 14.3% from a year earlier. It posted a net loss of $53.4M. In fiscal 2025 capital spending exceeded operating cash flow by $19.3M. At September 30, 2026 it held $66.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about RxSight, Inc.
- Net worth
- RxSight, Inc. has a market value (market cap) of $202.1M at the latest share price, and shareholders' equity of $254.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $134.5M (-3.9% year on year), with a net loss of $38.9M. Over the 12 months to September 30, 2026: revenue $121.8M, net loss $53.4M.
- Cash flow
- In fiscal 2025 operations used $15.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- RxSight, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What RxSight, Inc. does
RxSight, Inc. is registered with the SEC under industry code SIC 3851 (Ophthalmic Goods). Its shares trade on NASDAQ under the ticker RXST.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $134.5M | -$38.9M | -$0.95 | -$19.3M |
| 2024 | $139.9M | -$27.5M | -$0.71 | -$22.4M |
| 2023 | $89.1M | -$48.6M | -$1.41 | -$46.4M |
| 2022 | $49M | -$66.8M | -$2.41 | -$61.2M |
| 2021 | $22.6M | -$48.7M | -$3.57 | -$46.6M |
| 2021 | $14.7M | $27.6M | $0.15 | -$37.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RXST ranks in Health care
Latest SEC filings
What RxSight, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 19% to $24.6M versus the same quarter last year; diluted EPS -$0.39 versus -$0.24.
- November 3, 2026
- November 2, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- September 8, 2026Form SC TO-I/A filing SC TO-I/A
- August 25, 2026Form SC TO-I/A filing SC TO-I/A
- August 19, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026Form SC TO-I filing SC TO-I
Insider trades
What the people running RxSight, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $118K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Weinberg EricSee remarks | Exercised options | 35,168 | $152.6K |
| September 2, 2026 | Weinberg EricSee remarks | Sold | 2,041 | $14.2K |
| September 2, 2026 | Goldshleger IlyaChief Operating Officer | Sold | 2,041 | $14.2K |
| September 2, 2026 | Wilterding MarkChief Financial Officer | Sold | 7,765 | $54K |
| September 2, 2026 | Kurtz Ronald M MDChief Medical Officer | Sold | 5,100 | $35.5K |
| August 31, 2026 | Weinberg EricSee remarks | Exercised options | 5,370 | - |
| August 31, 2026 | Goldshleger IlyaChief Operating Officer | Exercised options | 5,370 | - |
| August 31, 2026 | Wilterding MarkChief Financial Officer | Exercised options | 20,441 | - |
Who owns RXST
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock Portfolio Management LLC13G, passive | 7.2% | July 17, 2026 |
| BlackRock, Inc.13G, passive | 6.9% | October 27, 2026 |
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 6% | August 19, 2026 |
| Millennium Management LLC13G, passive with 2 related filers | 5.1% | November 2, 2026 |
| Artisan Partners Asset Management Inc.13G, passive with 3 related filers | 5% | May 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 151 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,790,408 | +2,603,316 |
| Millennium Management LLC | 3,030,287 | +970,828 |
| No Street GP LP | 2,055,000 | +55,000 |
| Nomura Holdings Inc | 2,000,060 | 0 |
| D. E. Shaw & Co., Inc. | 1,985,215 | +25,483 |
| Vanguard Capital Management LLC | 1,675,582 | -17,353 |
| Aqr Capital Management LLC | 1,533,826 | +897,697 |
| Federated Hermes, Inc. | 1,201,195 | +120,483 |
| Two Sigma Investments, LP | 1,147,048 | -153,212 |
| Healthcare of Ontario Pension Plan Trust Fund | 1,131,400 | 0 |
| UBS Group AG | 1,016,066 | +776,610 |
| Jacobs Levy Equity Management, Inc | 998,569 | -67,752 |
| Marshall Wace, Llp | 995,916 | +983,191 |
| Geode Capital Management, LLC | 984,978 | +65,085 |
| State Street Corp | 851,512 | +50,189 |
| Point72 Asset Management, L.P. | 778,252 | +44,945 |
| Grandeur Peak Global Advisors, LLC | 722,440 | +256,848 |
| Schonfeld Strategic Advisors LLC | 701,417 | +509,717 |
| Citadel Advisors LLC | 700,736 | -417,983 |
| Trexquant Investment LP | 607,935 | +470,948 |
Insiders
14 insiders reported holding 1,103,513 shares in total, about $5.4M at the last price.
| Holder | Shares |
|---|---|
| Weinberg EricSee remarks | 235,516 |
| Corley Jesse AndersonDirector | 86,227 |
| Tammenoms Bakker JulietDirector | 85,183 |
| Goldshleger IlyaChief Operating Officer | 81,509 |
| Palmisano Robert JDirector | 78,076 |
| Warner Robert KeithDirector | 78,076 |
| Andrews JulieDirector | 78,076 |
| Link William J PhdDirector | 74,892 |
| Fountain TamaraDirector | 72,582 |
| Kurtz Ronald M MDChief Medical Officer | 71,775 |
Questions about RXST
What does RxSight, Inc. do?
RxSight, Inc. is a company in the Health care sector, listed on NASDAQ as RXST. Its shares trade on NASDAQ under the ticker RXST.
What is RxSight, Inc.'s net worth?
RxSight, Inc. has a market value (market cap) of $202.1M at the latest share price, and shareholders' equity of $254.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is RxSight, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $53.4M on revenue of $121.8M.
How much revenue does RxSight, Inc. make?
Over the twelve months to September 30, 2026 RxSight, Inc. reported revenue of $121.8M. That is 14.3% less than a year earlier.
When did RxSight, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is RxSight, Inc.'s next earnings report?
RxSight, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RXST with
Follow RXST
Get an email when RxSight, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values RxSight, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.